Tamoxifen has been in clinical use for the treatment of cancer since the 1970s but the relatively recent discovery of endoxifen (Stearns et al., 2003), coupled with an increased understanding of the phenotypic variability of CYP2D6 (Zanger et al., 2004), has suggested opportunities for further optimization of therapy. This evidence concerns the gene CYP2D6 and cancer.